Trends in oral anticoagulant use in patients with atrial fibrillation in Belgium from 2013 to 2019: a nationwide cohort study
M Grymonprez, TL De Backer, A Capiau… - British Journal of …, 2023 - Wiley Online Library
Aim Non‐vitamin K antagonist oral anticoagulants (NOACs) are increasingly preferred over
vitamin K antagonists (VKAs) in atrial fibrillation (AF) management. However, differences in …
vitamin K antagonists (VKAs) in atrial fibrillation (AF) management. However, differences in …
Trends in oral anticoagulant use in patients with atrial fibrillation in Belgium from 2013 to 2019: A nationwide cohort study
M Grymonprez, TL De Backer… - British journal of …, 2023 - pubmed.ncbi.nlm.nih.gov
Aim Non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly preferred over
vitamin K antagonists (VKAs) in atrial fibrillation (AF) management. However, differences in …
vitamin K antagonists (VKAs) in atrial fibrillation (AF) management. However, differences in …
Trends in oral anticoagulant use in patients with atrial fibrillation in Belgium from 2013 to 2019: a nationwide cohort study
M Grymonprez, TL De Backer, A Capiau… - European Heart …, 2022 - academic.oup.com
Background Non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly
preferred over vitamin K antagonists (VKAs) in atrial fibrillation (AF) management. However …
preferred over vitamin K antagonists (VKAs) in atrial fibrillation (AF) management. However …
Trends in oral anticoagulant use in patients with atrial fibrillation in Belgium from 2013 to 2019: a nationwide cohort study
M Grymonprez, TL De Backer, A Capiau, D Vauterin… - academia.edu
Background: Non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly
preferred over vitamin K antagonists (VKAs) in atrial fibrillation (AF) management. However …
preferred over vitamin K antagonists (VKAs) in atrial fibrillation (AF) management. However …
[HTML][HTML] Trends in oral anticoagulant use in patients with atrial fibrillation in Belgium from 2013 to 2019: a nationwide cohort study
M Grymonprez, T De Backer, A Capiau… - BRITISH JOURNAL …, 2023 - biblio.ugent.be
Aim Non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly preferred over
vitamin K antagonists (VKAs) in atrial fibrillation (AF) management. However, differences in …
vitamin K antagonists (VKAs) in atrial fibrillation (AF) management. However, differences in …
[PDF][PDF] Trends in oral anticoagulant use in patients with atrial fibrillation in Belgium from 2013 to 2019: A nationwide cohort study
M Grymonprez, TL De Backer, A Capiau, D Vauterin… - 2022 - pure.eur.nl
Aim: Non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly preferred over
vitamin K antagonists (VKAs) in atrial fibrillation (AF) management. However, differences in …
vitamin K antagonists (VKAs) in atrial fibrillation (AF) management. However, differences in …
[PDF][PDF] Trends in oral anticoagulant use in patients with atrial fibrillation in Belgium from 2013 to 2019: A nationwide cohort study
M Grymonprez, TL De Backer, A Capiau, D Vauterin… - 2022 - researchgate.net
Aim: Non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly preferred over
vitamin K antagonists (VKAs) in atrial fibrillation (AF) management. However, differences in …
vitamin K antagonists (VKAs) in atrial fibrillation (AF) management. However, differences in …
[PDF][PDF] Trends in oral anticoagulant use in patients with atrial fibrillation in Belgium from 2013 to 2019: A nationwide cohort study
M Grymonprez, TL De Backer, A Capiau, D Vauterin… - 2022 - researchportal.vub.be
Aim: Non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly preferred over
vitamin K antagonists (VKAs) in atrial fibrillation (AF) management. However, differences in …
vitamin K antagonists (VKAs) in atrial fibrillation (AF) management. However, differences in …
[PDF][PDF] Trends in oral anticoagulant use in patients with atrial fibrillation in Belgium from 2013 to 2019: A nationwide cohort study
M Grymonprez, TL De Backer, A Capiau, D Vauterin… - 2022 - backoffice.biblio.ugent.be
Aim: Non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly preferred over
vitamin K antagonists (VKAs) in atrial fibrillation (AF) management. However, differences in …
vitamin K antagonists (VKAs) in atrial fibrillation (AF) management. However, differences in …
Trends in oral anticoagulant use in patients with atrial fibrillation in Belgium from 2013 to 2019: a nationwide cohort study.
M Grymonprez, TL De Backer, A Capiau… - British Journal of …, 2022 - europepmc.org
Aim Non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly preferred over
vitamin K antagonists (VKAs) in atrial fibrillation (AF) management. However, differences in …
vitamin K antagonists (VKAs) in atrial fibrillation (AF) management. However, differences in …